HC Wainwright reaffirmed their buy rating on shares of Vertex Pharmaceuticals ( NASDAQ:VRTX – Free Report ) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $380.00 target price on the pharmaceutical company's stock. VRTX has been the topic of a number of other reports. Westpark Capital assumed coverage on Vertex Pharmaceuticals in a research note on Thursday, May 25th. They set a hold rating on the stock. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $384.

https://www.dailypolitical.com/2023/08/03/vertex-pharmaceuticals-vrtx-buy-rating-reiterated-at-hc-wainwright.html

#dailypolitical